Quick Answer
Bicara Therapeutics Inc. reported Net Income of -$137.95 million for fiscal year 2025.
Bicara Therapeutics Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$137.95M | -102.9% |
| 2024 | -$68.00M | -30.8% |
| 2023 | -$51.98M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$36.33M | -107.8% | -32.6% |
| June 30, 2025 | -$27.39M | -60.6% | +25.7% |
| March 31, 2025 | -$36.85M | -194.6% | -110.8% |
| September 30, 2024 | -$17.48M | +23.5% | -2.5% |
| June 30, 2024 | -$17.05M | -83.6% | -36.3% |
| March 31, 2024 | -$12.51M | -68.8% | +45.2% |
| September 30, 2023 | -$22.84M | — | -146.0% |
| June 30, 2023 | -$9.29M | — | -25.3% |
- Bicara Therapeutics Inc. showed a decrease of -102.9% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, Bicara Therapeutics Inc.’s net income has declined by 165.4% (from -$51.98 million to -$137.95 million).
- The most recent figure is from Bicara Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: